Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide Lysosome-targeting chimera technology has been utilized to degrade proteins of interest via the endosome–lysosome pathway mediated by endogenous ligands that engage cell-surface transmembrane proteins. Despite their promising potential, current approaches remain limited by the tissue-specific expression of surface receptors required for endocytosis. Prostate-specific membrane antigen (PSMA) is highly and specifically expressed in prostate cancer, driving significant progress in PSMA-targeted therapies, particularly radioligand therapy and antibody-drug conjugates, through PSMA-mediated internalization. Leveraging this phenomenon, we developed PSMA-targeting chimeras (PATACs), a novel and readily accessible class of heterobispecific small molecules designed for membrane protein degradation. PATACs facilitate the cointernalization of a target protein of interest, directing it into the lysosomal degradation pathway. As a proof of concept, A4, a representative PATAC, induced rapid and dose-dependent degradation of programmed cell death ligand 1 (PD-L1), with significant reduction observed within 4 h at concentrations up to 100 nM. Consequently, this degradation potently enhanced T-cell-mediated killing of LNCaP cells in a coculture system. Molecular dynamics simulations revealed that PATAC A4, featuring a short and rigid linker, exhibits enhanced conformational stability within the PSMA- A4 -PD-L1 ternary complexes. These findings reveal PATACs as a promising new class of bifunctional small-molecule modalities for the precise manipulation of membrane proteins and targeted therapy in prostate cancer.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: